Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.
Lee
Chen-Hsiang
CH
Wang
Ming-Chung
MC
Huang
I-Wen
IW
Chen
Feng-Jui
FJ
Lauderdale
Tsai-Ling
TL
D000081:Acetamides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017576:Daptomycin / Q000627:therapeutic use*; D006801:Humans; D000069349:Linezolid; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000472:pathogenicity*; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010068:Oxacillin / Q000627:therapeutic use*; D023303:Oxazolidinones / Q000627:therapeutic use; D017334:Teicoplanin / Q000627:therapeutic use; D020713:Vancomycin Resistance
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D017334:Teicoplanin; D000069349:Linezolid; D017576:Daptomycin; D010068:Oxacillin